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Stage IV metastatic melanoma patients historically have a poor prognosis with 5–10% 5-
year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4
(CTLA4), is one of the first treatments to provide beneficial durable responses in advanced
melanoma. However, less than 25% of those treated benefit, treatment is expensive, and
side effects can be fatal. Since soluble (s) CTLA4 may mediate inhibitory effects previously
ascribed to the membrane-bound isoform (mCTLA4), we hypothesized patients benefiting
from ipilimumab have higher serum levels of sCTLA4. We found that higher sCTLA4 levels
correlated both with response and improved survival in patients treated with ipilimumab
in a small patient cohort [patients with (n=9) and without (n= 5) clinical benefit]. sCTLA4
levels were statistically higher in ipilimumab-treated patients with response to ipilimumab.
In contrast, sCTLA4 levels did not correlate with survival in patients who did not receive
ipilimumab (n=11).These preliminary observations provide a previously unrecognized link
between serum sCTLA4 levels and response to ipilimumab as well as to improved survival
in ipilimumab-treated melanoma patients and a potential mechanism by which ipilimumab
functions.
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INTRODUCTION
Cutaneous melanoma is the third most common skin cancer and
the most aggressive of all skin cancers with increasing incidence
and worsening survival over the past few decades. Only 5–10%
of stage IV melanoma patients survive beyond 5 years (1). Ipil-
imumab is the first FDA approved therapy to show an overall
survival (OS) benefit for metastatic melanoma in randomized
clinical trials (2).
Ipilimumab is a monoclonal antibody with specificity against
cytotoxic T-lymphocyte antigen 4 (CTLA4),an inhibitory immune
mediator with both membrane-bound (mCTLA4) and soluble
(sCTLA4) forms (3). mCTLA4 is present in intracytoplasmic vesi-
cles of T cells (4) and it is constitutively expressed at low levels in
resting T cells (5). CTLA4 is upregulated on activated T cells (6)
and translocates to the cell surface to deliver a negative signal to
“put the brakes on” T cells (7, 8). CTLA4 is important to maintain
self-tolerance and prevent autoimmunity (7, 9, 10). This activity
is classically thought to be mediated by the full-length mCTLA4.
In addition to mCTLA4, other alternatively spliced mRNA tran-
scripts of CTLA4 have been detected, including a secretable soluble
form, sCTLA4 (3, 11). Recently, sCTLA4 has been shown to be
an important immune regulator by inhibiting antigen-specific T
cell proliferation and cytokine production (12). Therefore, we
hypothesized that patients’ serum levels of sCTLA4 may reflect
clinical benefit from treatment with the monoclonal antibody to
CTLA4, ipilimumab.
MATERIALS AND METHODS
IDENTIFICATION OF PATIENTS AND PATIENT CHARACTERISTICS
After internal regulatory review approval was obtained, the John
Wayne Cancer Institute (JWCI) database was searched for those
patients who had received ipilumumab. This database was estab-
lished in 1971 and currently holds patient clinical characteristics,
treatment and outcome data for 14,983 melanoma patients. The
database is updated yearly for patient survival and outcome data
and in addition is linked with a tissue, peripheral blood cell, and
serum biorepository.
We identified 14 patients who received ipilumumab who also
had prospectively collected pre-treatment serum available for
study. The time range between serum collection and ipilimumab
administration was 1–85 months with an average time range of
25 months. Determination of clinical benefit was based on the
response evaluation criteria in solid tumors (RECIST), which
designates patients having a complete or partial response, sta-
ble disease, or progressive disease during treatments. We defined
patients with clinical benefit (n= 9) as those with complete or
partial response or stabilization of disease and patients without
clinical benefit (n= 5) as those with progression of disease. Scores
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were determined by serial scans by treating medical and surgical
oncologists. Median followup for patients was 8 years.
We also identified Stage IV melanoma patients who had
not received ipilimumab (n= 11). Serum sCTLA4 levels were
measured for this group and correlated with survival. Demo-
graphic features from all patients (14 ipilimumab-treated+ 11
non-ipilimumab-treated) including age, sex, primary tumor char-
acteristics (anatomical site, Clark level, Breslow depth, ulceration),
and additional immune (previous immunotherapy) and surgical
treatments (metastectomy) were collected and compared. In addi-
tion, complications from ipilimumab treatment were collected
from ipilimumab-treated patients.
SERUM CTLA4 MEASUREMENT
sCTLA4 levels were measured by ELISA (E-bioscience Bender Med
System Vienna, Austria), according to the manufacturer’s instruc-
tions. Samples were blindly tested in triplicate to generate mean
values used in the analysis. Two-tailed Mann–Whitney test was
used to determine statistical significance with p< 0.05 as statisti-
cally significant. The lowest sensitivity threshold was 100 pg/mL.
The analytical response was linear approximately between 0.1 and
1.2 of absorbance values corresponding to 100–50,000 pg/mL as
assessed by serial dilution test (13). Receiver operating character-
istic (ROC) curve analysis was used to determine the cutoff of
sCTLA4 levels to classify patients as those with vs. those without
clinical benefit. For samples below the limit of detection, a value
of 0 pg/mL is arbitrarily assigned.
SURVIVAL ANALYSIS
Survival rates were estimated by the Kaplan–Meier method and
compared using log-rank test. In addition, both univariable and
multivariable Cox proportional hazard regression analyses were
performed to examine the association between sCTLA4 level and
survival.
MULTIVARIABLE ANALYSIS
Multivariable analysis was performed to determine the indepen-
dent association of sCTLA4 levels and survival. Primary outcome
measures were ipilimumab benefit, 5-year OS, defined as period
from ipilimumab administration until death. Statistical analysis
was performed with SAS 9.2 (Cary, NC, USA). P-value< 0.05 was
considered significant.
RESULTS
CHARACTERISTICS OF PATIENTS
Characteristics of the patients with benefit from ipilimumab
(n= 9) and those without benefit from ipilimumab (n= 5) are
shown in Table 1. Demographics (sex, age, primary location, com-
plications, or M status) and treatments (previous immunotherapy
or number of surgeries) were similar between the two groups.
Characteristics of the patients who did not receive ipilimumab
(n= 11) are shown in Table 2.
SOLUBLE CTLA4 SERUM LEVELS OF MELANOMA PATIENTS
Sera from patients treated with ipilumumab were tested for
sCTLA4 levels by ELISA, and levels compared between those with
and without clinical benefit. Mean sCTLA4 levels for the patients
Table 1 | Demographics of ipilimumab-treated melanoma patients
with clinical benefit vs. patients without clinical benefit.
Demographic Patients with
clinical benefit
n (%)
Patients without
clinical benefit
n (%)
p-Value
Sex 1.0
Male 5 (55) 3 (60)
Female 4 (45) 2 (40)
Age 0.51
Average (range) 54 (42–67) 50 (29–66)
Previous immunotherapy 0.41
Yes 6 (67) 4 (80)
No 3 (33) 1 (20)
Complications 0.50
Yes 2 (22) 0 (0)
No 7 (78) 5 (100)
Metastectomy 1.00
Yes 6 (67) 4 (80)
No 3 (33) 1 (20)
Primary 0.33
Trunk 2 (22) 0 (0)
Mucosal 2 (22) 0 (0)
Extremity 3 (33) 3 (60)
Head and neck 2 (22) 1 (20)
Unknown 0 (0) 1 (20)
M status 0.34
M1a 1 (12) 1 (20)
M1b 3 (33) 0 (0)
M1c 5 (55) 4 (80)
sCTLA4 level 0.03
sCTLA4 level <200 2 (22) 4 (80)
sCTLA4 level >200 7 (78) 1 (20)
with benefit from ipilimumab was 2,417 pg/mL with median levels
of 918 pg/mL (range 0–8, 930 pg/mL). Mean sCTLA4 levels for the
patients without benefit from ipilimumab was 208 pg/mL with
median levels of 0 pg/mL (range 0–995 pg/mL). The average levels
of sCTLA4 in serum from patients with clinical benefit were higher
than from those without clinical benefit (p< 0.05) (Figure 1).
To determine sCTLA4 levels predictive of patients with benefit,
we performed ROC curve analysis, which predicted sCTLA4 levels
of ≤200 pg/mL as a cutoff for prediction of those without benefit.
Based on this cutoff, the sensitivity of sCTLA4 levels for prediction
of clinical benefit was 77.8%, specificity was 80%, positive predic-
tive value of sCTLA4 levels was 87%, and negative predictive value
was 67%. Two-tailed Mann–Whitney test confirmed that sCTLA4
levels>200 were predictive of response to ipilimumab (Figure 1).
OS OF sCTLA4 LEVELS≤200 VS.>200
To determine whether patients treated with ipilimumab derive
survival benefit based on sCTLA4 levels, we examined survival
rates using a cutoff sCTLA4 level >200 pg/mL, determined by
ROC analysis. Those with sCTLA4 levels >200 pg/mL had a
higher percentage with 5-year OS (70 vs. 16.6% for sCTLA4 lev-
els ≤200 pg/ml; p= 0.02). Median OS was 5.9 and 43.2 months
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Table 2 | Demographics of 11 melanoma patients not treated with
ipilimumab.
Demographic sCTLA4 ≤200
pg/mL (n %)
sCTLA4 >200
pg/mL (n %)
p-Value
Sex 0.34
Male 3 (100) 6 (75)
Female 0 (0) 2 (25)
Age 0.40
Average 41 52
Primary 0.17
Trunk 2 (66.7) 3 (37.5)
Extremity 0 (0) 5 (62.5)
Head and neck 1 (33.3) 0 (0)
M status 0.38
M1a 5 (33.3) 4 (50)
M1b 0 (0) 2 (25)
M1c 2 (66.7) 2 (25)
FIGURE 1 | Serum sCTLA4 levels correlate with clinical benefit to
ipilimumab treatment. sCTLA4 levels were measured by ELISA and
individual values plotted according to clinical response. Values are
expressed as the mean value of triplicate wells. The sensitivity of the ELISA
was 100 pg/mL. Two-tailed Mann–Whitney test was used to evaluate the
significance of the differences between patients who received (n= 9) or did
not receive (n=5) benefit from ipilimumab treatment. The cutoff sCTLA4
level for prediction of clinical benefit was determined using a threshold of
200 pg/mL based on ROC curve analysis.
for patients with sCTLA4≤200 pg/mL and sCTLA4>200 pg/mL,
respectively (Figure 2). Multivariable analysis showed that no
covariate other than elevated sCTLA4 level was associated with
prolonged 5-year OS (Table 3).
Table 3 | Univariable Cox Proportional hazard regression analysis of
5-year overall survival.
Variable p-Value Hazard ratio 95% CI
Elisa <200 vs. >200 0.04 5.29 1.06–26.4
Male vs. female 0.97 0.97 0.26–3.66
Age at diagnosis 0.52 0.97 0.90–1.06
Breslow depth 0.67 1.02 0.94–1.11
Ulcerated vs. non-ulcerated 0.51a NA NA
M1abc 0.32
M1a vs. M1c 0.20 3.19 0.55–18.59
M1b vs. M1c 0.64 0.60 0.07–5.35
aBy log-rank test (Hazard ratio approached zero so log-rank test was done instead).
Multivariable analysis incorporating all the above variables showed that all the
other variables except (ELISA) were not significant. Thus, the univariable model
with ELISA is the final model.
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FIGURE 2 | Overall survival after ipilimumab treatment is greater in
patients with serum CTLA4 levels above 200 pg/mL for
ipilimumab-treated patients. Overall survival curves (5 years) of patients
treated with ipilimumab comparing those with greater than 200 pg/mL
serum sCTLA4 to those with less than or equal to 200 pg/mL.
To determine whether sCTLA4 levels correlate with survival
in general, rather than only in those patients who are treated
with anti-CTLA4, we also tested stage IV melanoma patients who
had not received ipilimumab (n= 11). Using the same cutoff of
200 pg/mL, the two survival curves were not statistically different,
with 33.4 and 29.6 months median OS for patients with sCTLA4
≤200 pg/mL and sCTLA4 >200 pg/mL, respectively (p= 0.60)
(Figure 3).
DISCUSSION
Here, we report serum sCTLA4 levels of ipilimumab-treated
patients with advanced melanoma from samples collected prior to
ipilimumab therapy. Our preliminary findings show that elevated
serum levels of sCTLA4 are associated with clinical benefit to ipil-
imumab in this initial cohort. Patients with elevated sCTLA4 also
showed a significant survival benefit over those with low sCTLA4
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FIGURE 3 | Overall survival after stage IV diagnosis in patients not
receiving ipilimumab treatment is not different in patients with serum
sCTLA4 levels above 200 pg/mL. Overall survival curves (up to 5 years) of
patients who did not receive ipilumumab comparing those with greater than
200 pg/mL serum sCTLA4 to those with less than or equal to 200 pg/mL.
levels (defined as <200 pg/mL). It is unclear, why some patients
with melanoma have enhanced circulating levels of sCTLA4; how-
ever, increased levels of serum sCTLA4 have also been reported in
patients with breast cancer (14). Elevated serum sCTLA4 may be
due to increased secretion from T regulatory cells (Tregs), as these
cells are a prominent source of sCTLA4 (15). Additional analysis
of sCTLA4 levels from 11 non-ipilimumab-treated patients indi-
cate levels of sCTLA4 alone are not correlated with survival. Taken
together, these data suggest patients with higher circulating lev-
els of sCTLA4 receive clinical benefit to a drug, which binds this
target.
sCTLA4 has been shown to have an inhibitory effect on T
cell responses. Neutralization of sCTLA4 using soluble isoform-
specific antibodies increased T cell proliferation and cytokine pro-
duction (12). In fact, sCTLA4 inhibited production of cytokines
IFNγ, IL-2, IL-7, IL-13, and IL-17, yet activated the secretion of
immunosuppressive cytokines TGFβ and IL-10 (12, 15). Aside
from regulating cytokine production, there are a number of sce-
narios by which sCTLA4 might regulate the melanoma-specific
T cell response. First, sCTLA4 might compete with CD28 and
block T cell co-stimulation as does the membrane-bound form
(11, 16). In addition, sCTLA4 can induce the enzyme indoleamine
2,3 dioxygenase (IDO), which catabolizes tryptophan, leading
to an unfavorable microenvironment for effector T cells (17).
Lastly, it has been shown that a recombinant form of sCTLA4
(CTLA4-Ig) can stimulate transport of the FoxO3 transcrip-
tion factor to the nucleus (18). FoxO3 controls the magni-
tude of T cell responses by modulating the function of den-
dritic cells. Based on the ability of sCTLA4 to suppress T cell
responses through mechanisms described above, the treatment
of patients with ipilimumab may help to counteract sCTLA4-
induced immune suppression and promote protective T cell
responses.
As one of the first immune therapies to show survival advan-
tage in randomized clinical trial (2), ipilimumab is an impor-
tant advance in the treatment of metastatic melanoma. While
ipilimumab demonstrates a significant improvement in OS for
metastatic melanoma, ipilimumab is effective in less than 25% of
patients with tumor shrinkage in only 6–11% of patients (19). In
addition, ipilimumab-induced toxicities, usually autoimmune in
nature, can occur in up to 60% of patients treated with significant
morbidity. Ipilimumab toxicities range from mild side effects such
as diarrhea, rash, and weakness to irreversible panhypopituitarism,
colitis with perforation, and even death (20).
Ipilimumab has become a standard therapy for Stage IV
melanoma worldwide. Currently it is being evaluated in multi-
ple clinical trials and investigated for adjuvant therapy in high
risk Stage III and resected metastatic patients in EORTC 8071 as
well as ECOG E1609 (21). Clinical trials evaluating ipilimumab
as combination therapy with other agents including programed
death-1 (PD-1) pathway inhibitors are also currently underway
(22). Ipilimumab is also being used in clinical trials in cancers
other than melanoma such as lung (23) and prostate (24). As with
any potentially toxic therapy with relatively low response rates,
a predictive test to identify patients who may benefit is desired.
Previous studies have examined tumor sample microarray analy-
sis of mRNA expression of immune related genes (25), NY-ESO-1
antibody seropositivity (26), and absolute lymphocyte count (27);
however, the ability to discriminate those who might benefit from
ipilimumab is still out of reach. Our preliminary findings provide
rationale for further prospective validation in melanoma patients
as well as those with other malignancies for which ipilimumab is
being tested.
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